Evotec Reports New 5.03% Major Shareholding via Shares and Equity Swaps

An announcement from Evotec AG ( (EVO) ) is now available.

On January 12 and 13, 2026, Evotec SE reported changes in significant shareholdings to the German financial regulator, reflecting updated notifications of major holdings by investors including entities associated with Michael Kaufman. The filings indicate that these investors now control a combined 5.03% of Evotec’s voting rights through shares and equity-swap instruments, a development that underscores a notable institutional stake in the company and may signal increased investor engagement in its future strategic direction.

The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.

Spark’s Take on EVO Stock

According to Spark, TipRanks’ AI Analyst, EVO is a Neutral.

Evotec AG’s overall stock score is primarily impacted by its weak financial performance and concerning valuation metrics. The company is struggling with profitability and cash flow issues, reflected in a negative P/E ratio and lack of dividend yield. Technical analysis shows a bearish trend, further weighing on the score. Despite some positive developments from the earnings call, such as growth in the Biologics segment and strategic partnerships, these are not enough to offset the significant financial challenges.

To see Spark’s full report on EVO stock, click here.

More about Evotec AG

Evotec SE is a Germany-based biotechnology company specializing in drug discovery and development solutions, working with pharmaceutical and biotech partners to advance novel therapeutics across multiple disease areas on a global scale.

Average Trading Volume: 133,238

Technical Sentiment Signal: Sell

Current Market Cap: $1.3B

Find detailed analytics on EVO stock on TipRanks’ Stock Analysis page.